Lilly Expects Topline Data for 2 COVID-19 Drug Candidates by June-End, First Patient Dosed in Antibody Treatment Study: Japan Execs

June 3, 2020
Lilly Japan President Simone Thomsen (right), Japan R&D Chief Akikazu Yoshikawa Eli Lilly anticipates the readout of topline trial data for two COVID-19 drug candidates by the end of June, while a first-in-human study was just launched for another potential...read more